Inhibition of the tumor-promoting effects of TGF-beta in advanced prostate cancer
Description: PUBLIC HEALTH RELEVANCE: This research will investigate a promising new approach for treating advance androgen- independent prostate cancer, the second leading cause of cancer death in American men. The proposed strategy is to reduce the levels of transforming growth factor-beta, which is known to promote the progression of prostate cancer, including its metastasis to the bone and lungs, by neutralizing it with novel fusion proteins in which the extracellular domains of the transforming growth factor beta receptors are linked together by artificial linkers.
Funder: National Cancer Institute
Funding type: research
Funder scheme: R01
Start date: 2013-07-01
End date: 2019-05-31
Investigator: ANDREW P HINCK
Institution: UNIVERSITY OF TEXAS HLTH SCIENCE CENTER
Topic: TGF-β signaling in diseases
Subfield: Molecular Biology
Domain: Life Sciences
Funded outputs count: 25
Funder award ID: R01CA172886
OpenAlex ID: G504351007
